LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Aandelen Lijst・Exelixis Inc

Exelixis Inc

Gesloten

SectorGezondheidszorg

50.42 -1.87

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

50.31

Max

51.02

Belangrijke statistieken
By Trading Economics
Inkomsten	-34M 210M
Verkoop	12M 611M
K/W Sectorgemiddelde	16.606 50.102
EPS	0.87
Winstmarge	34.457
Werknemers	1,077
EBITDA	15M 258M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	-5.51% downside

Dividenden
By Dow Jones
Volgende Winsten	27 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.4B 13B
Vorige openingsprijs	52.29
Vorige sluitingsprijs	50.42

Nieuwssentiment

By Acuity

50%

124 / 344 Rangschikking in Healthcare

Exelixis Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 mei 2026, 23:44 UTC

Marktinformatie

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31 mei 2026, 23:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

31 mei 2026, 23:36 UTC

Marktinformatie

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31 mei 2026, 23:36 UTC

Marktinformatie

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31 mei 2026, 22:54 UTC

Acquisities, Fusies, Overnames

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29 mei 2026, 23:08 UTC

Acquisities, Fusies, Overnames

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 mei 2026, 23:06 UTC

Acquisities, Fusies, Overnames

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 mei 2026, 20:53 UTC

Winsten

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 mei 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

29 mei 2026, 20:33 UTC

Marktinformatie

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 mei 2026, 20:11 UTC

Winsten

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mei 2026, 19:47 UTC

Winsten

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 mei 2026, 19:36 UTC

Marktinformatie

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 mei 2026, 19:34 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

29 mei 2026, 19:34 UTC

Marktinformatie

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 mei 2026, 19:22 UTC

Marktinformatie

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 mei 2026, 19:05 UTC

Acquisities, Fusies, Overnames

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 mei 2026, 18:19 UTC

Marktinformatie

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 mei 2026, 18:12 UTC

Acquisities, Fusies, Overnames

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 mei 2026, 18:11 UTC

Marktinformatie

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 mei 2026, 18:10 UTC

Marktinformatie

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 mei 2026, 17:55 UTC

Winsten

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mei 2026, 17:55 UTC

Marktinformatie

NEAR Protocol Nearly Doubles in May -- Market Talk

29 mei 2026, 17:38 UTC

Marktinformatie

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 mei 2026, 17:00 UTC

Winsten

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

29 mei 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

29 mei 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

29 mei 2026, 16:02 UTC

Marktinformatie

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 mei 2026, 15:55 UTC

Marktinformatie

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Exelixis Inc Prognose

Koersdoel

By TipRanks

-5.51% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 47.7 USD -5.51%

Hoogste 56 USD

Laagste 40 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Exelixis Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Exelixis Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

124 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.